Vaxcyte, Inc. (PCVX)

Nasdaq · Healthcare · Biotechnology
$55.39-5.09%As of 2026-11-22 · USD
Last session low $55.27Last session high $58.48
52-week low $42.4052-week high $90.75
Market cap
$8.77B
Sector
Healthcare

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)38.4In the neutral range (30 to 70)
MACD (12, 26, 9)-1.02Below its signal line (-0.11); histogram -0.91
Bollinger %B (20, 2)-5%Below the lower band (56.04 to 68.42)
SMA 2062.23Price is 11.0% below
SMA 5062.13Price is 10.8% below
SMA 20057.80Price is 4.2% below
ATR (20)5.96% of priceAverage true range per day
52-week position27%In the lower part of the 42.40 to 90.75 range

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Insider filings, 90 daysNo purchases and 9 sales (about $5.2M).

More in Biotechnology